Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17604244 | 0.79 | ADORA1 (0.35) | ADORA1ADORA2AADORA2BPDE1C | |
| SCHEMBL17604167 | 0.79 | PRMT5 (0.36) | ADORA1ADORA2AADORA2BPDE5APDE1A | |
| Hydrochloric Acid SCHEMBL17604355 | 0.78 | PRMT5 (0.35) | ADORA1ADORA2AADORA2BPDE5APDE1A | |
| SCHEMBL6366943 | 0.78 | ADORA2A (0.38) | ADORA1ADORA2AADORA2BPDE5APDE1A | |
| SCHEMBL6365300 | 0.77 | ADORA1 (0.41) | ADORA1ADORA2AADORA2BPDE5APDE1A | |
| SCHEMBL6365678 | 0.76 | TSHR (0.39) | ADORA1ADORA2AADORA2BPDE5APDE1A | |
| SCHEMBL6366291 | 0.73 | PDE9A (0.46) | ADORA1ADORA2AADORA2BPDE5APDE1A | |
| SCHEMBL6366219 | 0.73 | ADORA1 (0.43) | ADORA1ADORA2AADORA2BPDE5APDE1A | |
| SCHEMBL6371104 | 0.73 | MEN1 (0.40) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL6366319 | 0.72 | KDM4E (0.48) | PDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | PDE3A, PDE5A, PDE2A | ADORA1 2644/4885ADORA2A 1325/4885ADORA2B 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.